Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.
2.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
3.

Dose-response relationship with venlafaxine.

Kelsey JE.

J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):21S-26S; discussion 26S-28S. Review.

PMID:
8784645
4.

Clinical evaluation of venlafaxine.

Ballenger JC.

J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. Review.

PMID:
8784646
5.

An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.

Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT.

CNS Spectr. 2009 Mar;14(3):144-54. Review.

PMID:
19407711
6.

Sertraline: a review of its use in the management of major depressive disorder in elderly patients.

Muijsers RB, Plosker GL, Noble S.

Drugs Aging. 2002;19(5):377-92. Review.

PMID:
12093324
7.

Spotlight on sertraline in the management of major depressive disorder in elderly patients.

Muijsers RB, Plosker GL, Noble S.

CNS Drugs. 2002;16(11):789-94. Review.

PMID:
12383038
8.

The role of venlafaxine in rational antidepressant therapy.

Feighner JP.

J Clin Psychiatry. 1994 Sep;55 Suppl A:62-8; discussion 69-70, 98-100. Review.

PMID:
7961545
9.

Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.

Maneeton N, Maneeton B, Eurviriyanukul K, Srisurapanont M.

Drug Des Devel Ther. 2013 Sep 27;7:1053-62. doi: 10.2147/DDDT.S46849. eCollection 2013. Review.

10.

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database.

Rudolph RL, Derivan AT.

J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):54S-59S; discussion 59S-61S. Review.

PMID:
8784648
11.

Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials.

Gibiino S, Marsano A, Serretti A.

Int J Neuropsychopharmacol. 2014 Jan;17(1):1-8. doi: 10.1017/S1461145713000746. Epub 2013 Aug 19. Review.

PMID:
23953038
12.

Pharmacologic profile and efficacy of venlafaxine.

Mendlewicz J.

Int Clin Psychopharmacol. 1995 Mar;10 Suppl 2:5-13. Review.

PMID:
7622816
13.

Cardiovascular safety in depressed patients: focus on venlafaxine.

Feighner JP.

J Clin Psychiatry. 1995 Dec;56(12):574-9. Review.

PMID:
8530334
14.

Safety and tolerance profile of venlafaxine.

Danjou P, Hackett D.

Int Clin Psychopharmacol. 1995 Mar;10 Suppl 2:15-20. Review.

PMID:
7622813
15.

Sertraline-induced behavioral activation during the treatment of an adolescent with major depression.

Guilé JM.

J Child Adolesc Psychopharmacol. 1996 Winter;6(4):281-5. Review.

PMID:
9231321
16.

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M.

J Clin Psychiatry. 2002 Sep;63(9):826-37. Review.

PMID:
12363125
18.

[Venlafaxine (velaxin) effectivity in treatment of depression: results of the recent investigations].

Veltishchev DY.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(11 Pt 2):79-81. Review. Russian. No abstract available.

PMID:
24429970
Items per page

Supplemental Content

Write to the Help Desk